Alcian blue is used to stain sulfated GAGs 10; this signal is amplified by use of a subsequent silver stain 11. Figure 1 provides a visual demonstration of the silver staining development process. As demonstrated, the Alcian blue signal representing GAGs separated by electrophoresis is amplified as the developing agent penetrates the polyacrylamide gel. Typically, the developing process will reduce silver and Alcian blue-stained GAGs in a density dependent fashion, with the edges of each band reducing first while the more densely staining regions in the center will stain last.
In the literature, the reported limit of detection of GAGs using PAGE-based approaches range from 0.5-1 µg12,13. To determine the limit of detection using our approach, heparan sulfate oligosaccharides of different polymer lengths (unfractionated heparin, dp20, dp10, dp6) were loaded onto a 22% polyacrylamide gel, then ran and stained as described above. Each oligosaccharide was loaded twice at two different masses: 1.0 µg and 0.5 µg. Figure 2 demonstrates that our technique can quite readily detect 0.5 µg of purified GAG. Notably, unfractionated heparin was least readily detected of the four different oligosaccharides tested, likely due to a wider distribution of polymer sizes that correspondingly reduces the density of each individual band.
To assess the efficiency of GAG purification from liquid biological samples, GAGs were isolated from two bronchoalveolar lavage (BAL) samples. As shown in Figure 3, the first sample marked as A used for GAG isolation was 1 mL of BAL fluid harvested from a mouse 24 h after intratracheal lipopolysaccharide (LPS) (3 mg/kg), administered to induce alveolar epithelial HS shedding 5. 10 µg of commercially available dp6 was added directly to this BAL fluid to serve as a "spike in" control to assess loss of GAGs during the isolation process. The second sample marked as B consisted of 10 mL of BAL fluid pooled from 3 mice who were given intratracheal LPS (3 mg/kg) 24 h prior, without exogenous GAG spike-in. Both samples were processed for GAG isolation simultaneously, and all 3 fractions eluted from the ion exchange column were retained and further processed in order to determine if any GAGs were present in the low-affinity and wash fractions. 2 µg of commercially purchased dp20, dp10, and dp6 heparan sulfate oligosaccharides were run in the PAGE gel alongside these samples to provide a reference by which to qualitatively assess the size of HS GAGs in each eluted fraction, as well as a reference to compare density with the 10 µg "spike in" control that underwent GAG isolation.
To demonstrate the use of this technique on solid tissue, heparan sulfate was isolated from a 15 mg piece of frozen mouse lung as described above. During the isolation and purification process, the low affinity fraction (0.2 M NaCl) eluted off the ion exchange column was retained and processed alongside the high affinity (2.7 M NaCl) fraction and run on the gel (Figure 4). 2 µg of commercially purchased dp20, dp10, and dp6 heparan sulfate oligosaccharides were run alongside these samples to provide a reference for size. As can be seen, the whole lung homogenate yielded an ample quantity of isolated HS, with the smallest fragments approximately equaling dp10 in size. The relative enrichment of Alcian blue/silver stain avid content GAGs in the 2.7 M NaCl fraction demonstrates that heparan sulfate binds with high affinity to the ion exchange columns and can be eluted off the column with high specificity. The whole lung homogenate yielded an ample quantity of isolated heparan sulfate (2.7 M NaCl fraction), with the smallest fragments approximately equaling dp10 in size.

Figure 1: Silver stain development process. Alcian blue staining of unfractionated heparin (UFH) or size-defined oligosaccharides (dp = degree of polymerization) separated by electrophoresis is amplified by silver staining. From left to right: UFH, dp20, dp10, dp6. Please click here to view a larger version of this figure.

Figure 2: Sensitivity of polyacrylamide gel and silver stain for the detection for heparan sulfate. Heparan sulfate oligosaccharides of different lengths (unfractionated heparin aka UFH, dp20, dp10, dp6) were onto a 22% polyacrylamide gel and ran and silver stained. Each oligosaccharide was loaded twice at two different masses: 1.0 µg (leftmost bands) and 0.5 µg (rightmost bands). Please click here to view a larger version of this figure.

Figure 3: Efficiency of GAG purification from liquid biological samples. GAGs isolated from two bronchoalveolar lavage (BAL) samples, labeled here as "A" and "B", were run on a 22% polyacrylamide gel and silver stained. Sample A consisted of 1mL of BAL fluid harvested from a mouse 24 h after treatment with 3 mg/kg intratracheal lipopolysaccharide (LPS). An additional 10 µg of dp6 HS were added to this sample as a "spike in" control. Sample B consisted of 10 mL of pooled BAL fluid collected from 3 mice 24 h after administration of LPS. Each sample was run alongside fractions from the ion exchange column eluted with either diluent ("wash") or low concentrations of NaCl (0.2 M). 2 µg of commercially purchased dp20, dp10, and dp6 heparan sulfate oligosaccharides were used as size references (leftmost bands). Please click here to view a larger version of this figure.

Figure 4: Measuring the size of heparan sulfates isolated and purified from a healthy mouse lung. Heparin sulfate content isolated and purified from 15 mg frozen sample of a lung isolated from a healthy mouse and run on a 22% polyacrylamide gel. Heparan sulfate was eluted from the ion exchange column with either low concentrations (0.2 M; low affinity fraction) or high concentrations (2.7 M, 16% solution; high affinity fraction) of NaCl. 2 µg of commercially purchased dp20, dp10, and dp6 heparan sulfate oligosaccharides were used as size references (leftmost bands). Please click here to view a larger version of this figure.
| NOTE: All solutions must be filtered (0.22μm) before use. |
| Solution | Recipe | Composition | Comments |
| Resolving gel/lower chamber running buffer (2 L or 4 L) | Boric acid, MW 61.83 | 2L: 12.36 g; 4L: 24.76 g | Desired concentration: 0.1 M |
| Tris base, MW 124.14 | 2L: 24.2 g; 4L: | Desired concentration: 0.1 M |
| Disodium EDTA MW 336.21 or dihydrate, MW 372.36 | 2L: 6.7 g or 7.4 g, respectively; 4L 13.4 g or 14.8 g, respectively | Desired concentration: 0.01 M |
| Deionized water | 2L or 4L | Adjust pH to 8.3 after fully dissolving reagents |
| Upper chamber running buffer (1 L) | Glycine | 93 g | Desired concentration: 1 M |
| Tris base, MW 124.14 | 24.2 g | Desired concentration: 0.2 M |
| Deionized water | 1 L | |
| Resolving gel, 22% total acrylamide (500mL) | Acrylamide, MW 71.08 | 100.1 g | Desired concentration: 20.02% w/v |
| N,N'-methylene-bis-acrylamide (bis, MW 154.17) | 10 g | Desired concentration: 2% w/v |
| Sucrose | 75 g | Desired concentration: 15% w/v |
| Resolving gel buffer | 500 mL | Bring to a total volume of 500mL; will require less than 500mL of buffer total |
| Resolving gel, 15% total acrylamide (400mL) | Acrylamide, MW 71.08 | 56.3 g | Desired concentration: 14.08% w/v |
| N,N'-methylene-bis-acrylamide (bis, MW 154.17) | 3.7 g | Desired concentration: 2% w/v |
| Sucrose | 20.8 g | Desired concentration: 15% w/v |
| Resolving gel buffer | 400 mL | Bring to a total volume of 400mL; will require less than 400mL of buffer total |
| Stacking gel (100 mL) | Acrylamide, MW 71.08 | 4.75 g | Desired concentration: 4.75% w/v |
| N,N'-methylene-bis-acrylamide (bis, MW 154.17) | 0.25 g | Desired concentration: 0.25% w/v |
| Resolving gel buffer | 100 mL | Add 80mL buffer and full dissolve reagents. Then adjust pH to 76.3 with hydrochloric acid, dropwise. Then bring to a total volume of 100 mL with resolving gel buffer. |
| Sample loading buffer (500 mL) | Sucrose | 250g | Desired concentration: 50% w/v |
| Phenol red | 500mg | Desired concentration: 1mg/mL |
| Bromophenol blue | 250mg | Desired concentration: 0.5mg/mL |
| Deionized water | 500mL | Bring to a total volume of 500mL; will require less than 500mL of water total |
| Heparin derived oligosacharide 'ladder' (2mL each) | dp6 | 0.1mg | NOTE: Recommend using heparin derived oligosaccharides 6 polymer subunits in length (aka degree of polymerization 6, or dp6) for the smallest band, dp20 for the largest band, and dp10 for middle band. However, other combinations can be used if desired. Desired concentration: 0.05 mg/mL |
| dp10 | 0.1mg |
| dp20 | 0.1mg |
| Deionized water | 3mL | Dissolve each oligosaccharide in separate tubes with 1mL each |
| Sample loading buffer | 3mL | Add 1mL (1:1 mixture) to each oligosaccharide solution |
Table 1: Solutions required for polyacrylamide gel electrophoresis of purified glycosaminoglycans. All solutions must be filtered (0.22 µm) before use.
| NOTE: All solutions must be filtered (0.22μm) before use. |
| Solution | Recipe | Composition | Comments |
| Alcian blue staining solution (500mL) | Alcian blue 8GX powder | 2.5g | Desired concentration: 0.5% w/v |
| 2% v/v glacial acetic acid | 500mL | |
| Silver stain (200 mL) | Deionized water | 192.7 mL | Prepare stain solution fresh; use within one week. |
| 7.6M sodium hydroxide | 2 mL | To make, add 3.04 g sodium hydroxide pellets to 10 mL water |
| Ammonium hydroxide | 3.3 mL | |
| 4M silver nitrate solution | 2 mL | To make, add 3.397 g silver nitrate to 5 mL water. Add dropwise while stirring to avoid precipitation. |
| Developing solution (501 mL) | Deionized water | 500 mL | Developing solution must be made fresh and used within 24 h. |
| 2.5% w/v citric acid | 1 mL | To make, add 100mg to 4 mL deionized water. Citric acid must be made fresh. |
| Formaldehyde | 250μL | |
| Stop solution (500 mL) | Deionized water | 300 mL | |
| Glacial acetic acid | 20 mL | |
| Methanol | 90 mL | |
Table 2: Solutions required for silver staining of glycosaminoglycans separated by polyacrlamide gel electrophoresis. All solutions must be filtered (0.22 µm) before use.